I expect positive results to be eventually released on Ereska. Because for years there has been a good bit of very positive research done on Ketamine for pain by Dr. Geo. D. Lundberg & others.
As for the pps of JAV , I have lived long enough to know that somebody ALWAYS knows something . And a small company like JAV is ripe for manipulation.
But in the end , when the FDA & manipulators are ready:
And when all the dust finally settles on Dyloject, I can reasonably see 100 - 150 million annual sales. And optimistiacally 150-200 million high end estimate.
Ereska, I reluctantly give the same estimates. Mostly because the potential use by the military is difficult to know.
Also , I see even bigger potential for somebody (not JAV) in selling ERESKA for "break through" pain & as pain treatment for cancer patients. Which is about a 2.5 billion dollar a year market now.
Which would suggest that if ERESKA took perhaps 10% of the cancer pain market , you could be looking at 250 million in annual sales from ERESKA alone.
Combining those estimates ,on the low end would suggest 200 - 300 million dollars in annual sales of both. And could suggest a potential JAV share price between 3.25 -5.00
The more optimistic estimates of 300-400 million, (which might could be made up by possible sales of ERESKA to the military), would suggest a Jav share price of 5 -6.50 . Which is close to WEDBUSH MORGANS target price of $6
It really seems to be just a matter of time.